Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | G-CSF | 28.0 | 57 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | G-CSF | 157.5 | 62 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 1 | G-CSF | 173.5 | 30 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | G-CSF | 1210.0 | 57 | |
N2759 | IL-1 alpha | 100 | ng/mL | 1 | G-CSF | 1131.5 | 48 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | G-CSF | 406.0 | 50 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 1 | G-CSF | 876.0 | 48 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | G-CSF | 705.0 | 53 | |
N2586 | IL-1 alpha | 100 | ng/mL | 1 | G-CSF | 482.5 | 54 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 16.0 | 50 | |
RA1869 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 24.0 | 43 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 22.0 | 62 | |
N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 20.5 | 54 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 17.0 | 57 | |
RA1931 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 20.0 | 73 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 20.5 | 50 | |
N2586 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 18.0 | 66 | |
RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 35.5 | 56 | |
RA1869 | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 57.0 | 59 | ||||
N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 54.0 | 49 | |
N2759 | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 70.0 | 58 | ||||
RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 45.0 | 59 | |
RA1931 | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 77.5 | 58 | ||||
N2586 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 72.0 | 59 | |
N2586 | Poly(I:C) | 2 | ug/mL | 1 | G-CSF | 111.0 | 35 |